Malignant B cell immunoblastic lymphoma expressing CD30 antigen in the terminal phase of a multiple myeloma.
An acute terminal phase of a Bence Jones kappa plasma cell myeloma developed 22 months after chemotherapy is presented. The patient's symptoms were fever, cytopenias, adenomegalies and hepatomegaly. A lymph node biopsy showed an immunoblastic polymorphic kappa B cell lymphoma, expressing CD30 antigen. After new polychemotherapy the patient died because of bleeding and infection. Autopsy revealed a decrease in the tumour with defective immunophenotype. The few reported cases have been reviewed with emphasis on clinical aspects, prognosis and morphology, The significance of CD30 positivity (activation marker) in a high-grade lymphoma is discussed.
Castrillo
J M
JM
Internal Medicine, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain.
Rivas
C
C
Alonso
C
C
Varela
A
A
Gonzalo
A
A
Jimenéz-Casado
M
M
D000368:Aged; D000943:Antigens, Differentiation / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D001536:Bence Jones Protein / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D017730:Ki-1 Antigen; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D009101:Multiple Myeloma / Q000276:immunology* / Q000378:metabolism / Q000473:pathology
D000943:Antigens, Differentiation; D000951:Antigens, Neoplasm; D017730:Ki-1 Antigen; D001536:Bence Jones Protein